ABIVAX to Participate in “Corporate Access” Event in San Francisco, January 8 – 10, 2018

Abivax announces that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

Logo
Dec. 21, 2017 07:00 UTC

PARIS--(BUSINESS WIRE)-- Regulatory News:

Abivax (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today announces that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

To schedule a meeting with ABIVAX, investors can register on the online system managed by the Company’s US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at Access@LifeSciAdvisors.com.

About ABIVAX (www.abivax.com)

ABIVAX is mobilizing the body’s natural immune machinery to treat patients with viral infections, autoimmune diseases and cancer. A clinical-stage company, ABIVAX leverages its antiviral and immune enhancing platforms to optimize candidates to cure HIV and treat inflammatory bowel diseases and liver cancer. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo : ABVX). More information on the company is available at www.abivax.com.

Follow us on Twitter @ABIVAX_

Contacts

ABIVAX
Finance
Didier Blondel, +33 1 53 83 08 41
didier.blondel@abivax.com
or
French Media
ALIZE RP
Caroline Carmagnol/Aurore Gangloff
+33 6 64 18 99 59 / +33 1 44 54 36 65
abivax@alizerp.com
or
Investors
LifeSci Advisors
Chris Maggos, +41 79 367 6254
chris@lifesciadvisors.com
or
US Media
LifeSci Public Relations
Matt Middleman, M.D., +1 646 627 8384
matt@lifescipublicrelations.com

Source: ABIVAX

MORE ON THIS TOPIC